0000899243-20-024940.txt : 20200911
0000899243-20-024940.hdr.sgml : 20200911
20200911212156
ACCESSION NUMBER: 0000899243-20-024940
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200909
FILED AS OF DATE: 20200911
DATE AS OF CHANGE: 20200911
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: El-Hibri Fuad
CENTRAL INDEX KEY: 0001380185
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33137
FILM NUMBER: 201172064
MAIL ADDRESS:
STREET 1: 2273 RESEARCH BLVD, SUITE 400
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Emergent BioSolutions Inc.
CENTRAL INDEX KEY: 0001367644
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 141902018
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 400 PROFESSIONAL DR, SUITE 400
CITY: GAITHERSBURG
STATE: MD
ZIP: 20879
BUSINESS PHONE: 240-631-3200
MAIL ADDRESS:
STREET 1: 400 PROFESSIONAL DR, SUITE 400
CITY: GAITHERSBURG
STATE: MD
ZIP: 20879
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-09-09
0
0001367644
Emergent BioSolutions Inc.
EBS
0001380185
El-Hibri Fuad
400 PROFESSIONAL DRIVE, SUITE 400
GAITHERSBURG
MD
20879
1
1
1
0
Chairman
Common Stock
2020-09-09
4
S
0
20000
102.80
D
1209523
D
Common Stock
2020-09-10
4
S
0
20000
102.66
D
1189523
D
Common Stock
2140463
I
By Intervac, L.L.C.
Common Stock
1524155
I
By Biovac, L.L.C.
The transaction was made by the Reporting Person pursuant to a trading plan adopted by Fuad El-Hibri Nancy El-Hibri JTWROS on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934 (the "Exchange Act").
The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.88 to $105.10.
The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.72 to $104.06.
The decrease in the number of shares of the Issuer's common stock held by Invervac, L.L.C. ("Intervac") does not reflect a sale of such shares by Intervac. On August 25, 2020 Intervac completed an internal restructuring pursuant to which Intervac redeemed all of the membership interests in Intervac held by members that were not controlled or managed, directly or indirectly, by Mr. El-Hibri or Mrs. El-Hibri. In consideration for such redemption, Intervac effected a pro-rata distribution of an aggregate of 2,177,121 shares of the Issuer's common stock to such non-affiliated members. After giving effect to the pro-rata distribution, Intervac is the direct owner of 2,140,463 shares of the Issuer's common stock and either Mr. El-Hibri or Mrs. El-Hibri serve as the trustee of each of the remaining members of Intervac.
(continued from footnote 4) Mr. El-Hibri disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Intervac for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein, which such pecuniary interest did not change as a result of the above described transaction.
Mr. El-Hibri, individually, and Mr. and Mrs. El-Hibri, as tenants by the entirety, collectively hold an aggregate 89.2% equity interest in Biovac, L.L.C, which in turn is the direct owner of 1,524,155 shares of the Issuer's common stock. Mr. El-Hibri disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Biovac, L.L.C. for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein.
/s/ Carl A. Valenstein, attorney-in-fact
2020-09-11